Novel Use of GLP-1 Receptor Agonist Therapy in HNF4A-MODY.
作者信息
Broome David T, Tekin Zehra, Pantalone Kevin M, Mehta Adi E
机构信息
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic Foundation, Cleveland, OH
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic Foundation, Cleveland, OH.
出版信息
Diabetes Care. 2020 Jun;43(6):e65. doi: 10.2337/dc20-0012. Epub 2020 Apr 7.
Abstract
摘要
相似文献
1
Novel Use of GLP-1 Receptor Agonist Therapy in HNF4A-MODY.胰高血糖素样肽-1受体激动剂疗法在肝细胞核因子4α-成熟型糖尿病中的新用途。
Diabetes Care. 2020 Jun;43(6):e65. doi: 10.2337/dc20-0012. Epub 2020 Apr 7.
2
Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection.在瑞典患者群体中，对 MODY1（HNF4A MODY）和 MODY3（HNF1A MODY）患者的β细胞和肠促胰岛素功能进行特征描述。
Acta Diabetol. 2012 Oct;49(5):349-54. doi: 10.1007/s00592-011-0312-y. Epub 2011 Jul 16.
3
Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.爱尔兰家族中 HNF1A-MODY 和 HNF4A-MODY 的鉴定：表型特征和治疗意义。
Diabetes Metab. 2011 Dec;37(6):512-9. doi: 10.1016/j.diabet.2011.04.002. Epub 2011 Jun 16.
4
Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database.MODY1（HNF4A 突变）和 MODY5（HNF1B 突变）的频率和特征：来自 DPV 数据库的分析。
J Clin Endocrinol Metab. 2019 Mar 1;104(3):845-855. doi: 10.1210/jc.2018-01696.
5
Maturity-Onset Diabetes of the Young (MODY) in Portugal: Novel , and Mutations.葡萄牙青年发病型糖尿病（MODY）：新型突变
J Clin Med. 2020 Jan 20;9(1):288. doi: 10.3390/jcm9010288.
6
Prolonged episodes of hypoglycaemia in HNF4A-MODY mutation carriers with IGT. Evidence of persistent hyperinsulinism into early adulthood.携带HNF4A-MODY突变且伴有糖耐量受损（IGT）的患者出现低血糖的持续发作。有证据表明直至成年早期仍存在持续性高胰岛素血症。
Acta Diabetol. 2016 Dec;53(6):965-972. doi: 10.1007/s00592-016-0890-9. Epub 2016 Aug 23.
7
Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy.采用胰高血糖素样肽-1受体激动剂单药治疗的肝细胞核因子1α基因（HNF1A）突变型成年发病型糖尿病患者的最佳血糖控制：对未来治疗的启示
J Endocr Soc. 2019 Oct 3;3(12):2286-2289. doi: 10.1210/js.2019-00278. eCollection 2019 Dec 1.
8
Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)?补体因子5、8和转甲状腺素蛋白能否用作青少年发病的成年型糖尿病1型（肝细胞核因子4α-青少年发病的成年型糖尿病）和青少年发病的成年型糖尿病3型（肝细胞核因子1α-青少年发病的成年型糖尿病）的生物标志物？
Diabet Med. 2008 Jul;25(7):788-91. doi: 10.1111/j.1464-5491.2008.02467.x.
9
Association of novel variants in the hepatocyte nuclear factor 4A gene with maturity onset diabetes of the young and early onset type 2 diabetes.肝细胞核因子 4A 基因中新变异与青年发病的成年型糖尿病及早发 2 型糖尿病的关联。
Clin Genet. 2011 Dec;80(6):541-9. doi: 10.1111/j.1399-0004.2010.01577.x. Epub 2010 Nov 10.
10
A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.一项英国全国性前瞻性研究显示，MODY 患者在停用胰岛素和二甲双胍后，治疗改变与遗传亚型和临床特征相关，可预测最佳血糖控制。
Diabetologia. 2018 Dec;61(12):2520-2527. doi: 10.1007/s00125-018-4728-6. Epub 2018 Sep 18.
引用本文的文献
1
Global perspectives on monogenic forms of diabetes.单基因糖尿病形式的全球视角。
Diabetologia. 2025 Jul 16. doi: 10.1007/s00125-025-06495-3.
2
Case Report: long-term misdiagnosis and follow-up of a patient with -MODY carrying a new mutation.病例报告：一名携带新突变的 -MODY 患者的长期误诊及随访
Front Endocrinol (Lausanne). 2025 Jun 16;16:1509135. doi: 10.3389/fendo.2025.1509135. eCollection 2025.
3
GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series.GLP-1受体激动剂和双重GIP/GLP-1受体激动剂治疗青少年发病的成年型糖尿病：一项描述性病例系列研究
BMJ Open Diabetes Res Care. 2025 Apr 23;13(2):e004885. doi: 10.1136/bmjdrc-2024-004885.
4
Decoding MODY: exploring genetic roots and clinical pathways.解读青少年发病的成年型糖尿病：探索遗传根源与临床路径。
Diabetol Int. 2025 Mar 14;16(2):257-271. doi: 10.1007/s13340-025-00809-x. eCollection 2025 Apr.
5
Maturity-Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report.携带HNF1B p.Glu105Lys突变的青年发病型成年糖尿病（MODY）患者使用替尔泊肽后胰岛素显著减少：一例报告
Clin Case Rep. 2025 Feb 3;13(2):e70173. doi: 10.1002/ccr3.70173. eCollection 2025 Feb.
6
Hidden MODY in Young Lean Women with Mild Glucose Intolerance Detected during Health Check-ups: Potential for Improved Pregnancy Outcomes through Preconception Care.在健康检查中发现的年轻消瘦轻度糖耐量异常女性中的隐匿性成年发病型糖尿病：通过孕前保健改善妊娠结局的潜力。
Intern Med. 2025 May 15;64(10):1603-1607. doi: 10.2169/internalmedicine.4244-24. Epub 2024 Oct 25.
7
Identification and precision therapy for three maturity-onset diabetes of the young (MODY) families caused by mutations in the HNF4A gene.鉴定并针对三个因 HNF4A 基因突变导致的青少年发病的成年型糖尿病（MODY）家系进行精准治疗。
Front Endocrinol (Lausanne). 2023 Aug 29;14:1237553. doi: 10.3389/fendo.2023.1237553. eCollection 2023.
8
Monogenic diabetes.单基因糖尿病。
Nat Rev Dis Primers. 2023 Mar 9;9(1):12. doi: 10.1038/s41572-023-00421-w.
9
Maturity-Onset Diabetes of the Young: Mutations, Physiological Consequences, and Treatment Options.青少年发病的成年型糖尿病：突变、生理后果及治疗选择
J Pers Med. 2022 Oct 25;12(11):1762. doi: 10.3390/jpm12111762.
10
How do I diagnose Maturity Onset Diabetes of the Young in my patients?我如何诊断我的患者是否患有青年发病的成年型糖尿病？
Clin Endocrinol (Oxf). 2022 Oct;97(4):436-447. doi: 10.1111/cen.14744. Epub 2022 May 2.
本文引用的文献
1
Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.GLP-1 受体激动剂治疗青年发病的成年型糖尿病患者的降糖效果及低血糖风险低：一项双盲、随机、交叉试验。
Diabetes Care. 2014 Jul;37(7):1797-805. doi: 10.2337/dc13-3007.
2
Mody-3: novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy.Mody-3：新型肝细胞核因子1A（HNF1A）突变与胰高血糖素样肽（GLP）-1受体激动剂治疗的效用
Endocr Pract. 2014 Feb;20(2):107-11. doi: 10.4158/EP13254.OR.
3
Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.因 HNF1A、HNF4A 和葡萄糖激酶基因突变导致的青年起病成年型糖尿病的患病率、特征和临床诊断：来自 SEARCH for Diabetes in Youth 的结果。
J Clin Endocrinol Metab. 2013 Oct;98(10):4055-62. doi: 10.1210/jc.2013-1279. Epub 2013 Jun 14.
4
Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.环磷酸腺苷（cAMP）升高激动剂对胰岛素分泌的多部位调节：胰高血糖素样肽1和胰高血糖素通过不同受体起作用的证据。
Pflugers Arch. 1997 Sep;434(5):515-24. doi: 10.1007/s004240050431.
5
Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.胰高血糖素样肽-1（一种葡萄糖依赖性促胰岛素多肽激素）胰腺β细胞受体的表达克隆
Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8641-5. doi: 10.1073/pnas.89.18.8641.
Zotero 插件